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1 
Symposium 
The Future of Reverse Payments in the 
Wake of FTC v. Actavis, Inc. 
Reverse payment patent litigation settlements, wherein 
the payments flow from plaintiff brand name drug companies 
to defendant generic competitors, often including agreements 
that the generic companies will delay market entry, have 
evaded consistent legal treatment and divided courts for over a 
decade. In December 2012, the United States Supreme Court 
granted the Federal Trade Commission’s petition for writ of 
certiorari to review FTC v. Watson Pharmaceuticals. In 
Watson, the Eleventh Circuit found that, absent sham 
litigation or fraud, reverse payment settlements are legal 
under antitrust law as long as the settlement agreement falls 
within the exclusionary scope of the patent. The Watson 
decision was followed mere months later by the Third Circuit’s 
In re K-DUR decision, concluding that reverse-payment 
settlements should be deemed presumptively unlawful under a 
quick-look rule of reason approach. Because “different courts 
have reached different conclusions” regarding the legality of 
reverse-payment settlements, the Supreme Court endeavored 
to resolve the circuit split in FTC v. Actavis, Inc. 
On June 17, 2013, with Justice Breyer writing the majority 
opinion in a 5-3 decision, the Supreme Court reversed the 
Eleventh Circuit, holding that governments and private 
plaintiffs have a cause of action under the antitrust laws 
against brand name and generic pharmaceutical companies 
engaging in reverse payment settlements. The Court directed 
lower courts reviewing such claims to apply a full rule of reason 
analysis to drug companies’ potentially anticompetitive 
conduct. 
In the spring of 2013, in anticipation of the Court’s 
decision, the Minnesota Journal of Law, Science & Technology 
invited scholars and practitioners who have analyzed and 
developed the jurisprudence of reverse payment settlements to 
respond to FTC v. Actavis, Inc. The following eleven response 
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pieces digest the opinion, critique both Justice Breyer’s 
majority opinion and Chief Justice Roberts’ dissent, and 
provide direction for courts and practitioners in navigating the 
new legal landscape of reverse-payment settlements in the 
wake of FTC v. Actavis, Inc. 
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